NDA 050608 · Pfizer
Unasyn
Ampicillin Sodium, Sulbactam Sodium · Injection
NovelLast checked: Nov 19, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Dec 31, 1986
Approved uses
2
Original approval plus efficacy supplements
Registered trials
804
170 Phase 3, 86 recruiting
FAERS reports
1,708
1,594 serious, 337 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 10, 2026.
INDICATIONS AND USAGE UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus , Escherichia coli , Efficacy for this organism in this organ system was studied in fewer than 10 infections. Klebsiella spp. (including K. pneumoniae ), Proteus mirabilis , Bacteroides fragilis , Enterobacter spp., and Acinetobacter calcoaceticus. NOTE: For information on use in pediatric patients (see PRECAUTIONS–Pediatric Use and CLINICAL STUDIES sections). Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli , Klebsiella spp. (including K. pneumoniae ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis ). While UNASYN is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to UNASYN should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to UNASYN. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 12, 1997 Supplement 19 · Efficacy Review
- Dec 31, 1986 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination Review
4 products under this application
- UNASYN · AMPICILLIN SODIUM EQ 10GM BASE/VIAL; SULBACTAM SODIUM EQ 5GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- UNASYN · AMPICILLIN SODIUM EQ 500MG BASE/VIAL; SULBACTAM SODIUM EQ 250MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
- UNASYN · AMPICILLIN SODIUM EQ 2GM BASE/VIAL; SULBACTAM SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- UNASYN · AMPICILLIN SODIUM EQ 1GM BASE/VIAL; SULBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ampicillin" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of AgePivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT01192789 · 4,070 participants · Start Feb 2008 · Primary completion Mar 2010
Drug: Amoxicillin · For: Severe Pneumonia
Sites: Matiari, Pakistan
- Randomized Trial of Amoxicillin Versus Placebo for (Fast Breathing) PneumoniaPivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT02372461 · 4,000 participants · Start Nov 9, 2014 · Primary completion Nov 2017
Drug: Placebo; Amoxicillin · For: Pneumonia; Tachypnea
Sites: Karachi, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pneumonia146
- pyrexia129
- dyspnoea88
- diarrhoea80
- pain77
- rash75
- drug ineffective65
- vomiting64
- sepsis63
- nausea61
- hepatic function abnormal59
- hypotension59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 104 |
| 2005 | 105 |
| 2006 | 95 |
| 2007 | 100 |
| 2008 | 90 |
| 2009 | 56 |
| 2010 | 122 |
| 2011 | 139 |
| 2012 | 106 |
| 2013 | 51 |
| 2014 | 65 |
| 2015 | 79 |
| 2016 | 91 |
| 2017 | 66 |
| 2018 | 59 |
| 2019 | 50 |
| 2020 | 44 |
| 2021 | 58 |
| 2022 | 40 |
| 2023 | 68 |
| 2024 | 60 |
| 2025 | 31 |
| 2026 | 29 |
Recalls
1 FDA enforcement reports for this application.
May 29, 2020 · Class II · Terminated
Presence of Particulate Matter: particulate matter identified after reconstitution.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Unasyn (Ampicillin Sod/Sulbactam Sod)
2024 spending
$84K
Beneficiaries
119
414 claims
Per beneficiary
$709
$20.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $115,514 |
| 2021 | $139,344 |
| 2022 | $90,943 |
| 2023 | $93,239 |
| 2024 | $84,427 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Revisiting mutational resistance to ampicillin and cefotaxime in Haemophilus influenzae.
Diricks M, Petersen S, Bartels L, et al. · Genome Med 2024 · Meta-Analysis, Systematic Review
- Antibiotic management of complicated appendicitis.
King DR, Browne AF, Birken GA, et al. · J Pediatr Surg 1983 · Clinical Trial, Comparative Study
- Ampicillin and gentamicin prophylaxis is superior to ampicillin alone in patients with prelabor rupture of membranes at term: the results of a randomized clinical trial.
Abu Shqara R, Glikman D, Goldinfeld G, et al. · Am J Obstet Gynecol 2025 · Comparative Study, Randomized Controlled Trial
- Antibiotics for community-acquired pneumonia in children.
Lodha R, Kabra SK, Pandey RM · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antibiotics for community-acquired pneumonia in children.
Kabra SK, Lodha R, Pandey RM · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- Antibiotics for bronchiolitis in children.
Spurling GK, Doust J, Del Mar CB, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.